Camizestrant vs Vepdegestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Vepdegestrant · Veppanu

Marketed by Rigel Pharmaceuticals and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT05654623 · Phase 3 · active, not recruiting

Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.

Next expected readout: December 2026 · NCT05909397 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)

Result source: NCT05654623

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCamizestrantVepdegestrant
PFS, median—Trial running · NCT077174503.7 vs 3.6vs Fulvestrantn 313NCT05654623
1 other result
OS, median—Trial running · NCT07717450—Trial running · NCT05909397
ORR—Trial running · NCT0771745010.9% vs 3.6%vs Fulvestrantn 221NCT05654623
Clinical benefit rate—Trial running · NCT0771745034.3% vs 28.7%vs Fulvestrantn 274NCT05654623

PFS, median

Camizestrant
—Trial running · NCT07717450
Vepdegestrant
3.7 vs 3.6vs Fulvestrantn 313NCT05654623
1 other result

OS, median

Camizestrant
—Trial running · NCT07717450
Vepdegestrant
—Trial running · NCT05909397

ORR

Camizestrant
—Trial running · NCT07717450
Vepdegestrant
10.9% vs 3.6%vs Fulvestrantn 221NCT05654623

Clinical benefit rate

Camizestrant
—Trial running · NCT07717450
Vepdegestrant
34.3% vs 28.7%vs Fulvestrantn 274NCT05654623
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Camizestrant: 4 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantVepdegestrant
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
7.8%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
—a
NCT05549505 · Phase 2 · registry result, not featured evidence
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
4%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
a
hot flush 24.8%
asthenia 20.8%
constipation 15.8%
NCT05549505 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Vepdegestrant

PFS 3.7 vs 3.6 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5 vs 2.1 Fulvestrant months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 10.9% (n=221) vs 3.6% (n=222) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 34.3% (n=274) vs 28.7% (n=272) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response NA vs 7.4 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Ki-67 Expression -71.4% (n=93) vs -72.9% (n=46) Anastrozole @ 2.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 71.4 Percent reduction as posted
Pathological Complete 1% (n=102) vs 0% (n=50) Anastrozole @ 22.57wk
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
mPEPI Score 0 20.6% (n=102) vs 20% (n=50) Anastrozole @ 22.57wk
event count · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
Breast Conserving Surgery 69.6% (n=102) vs 54% (n=50) Anastrozole
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
Stable Disease 37.3% (n=102) vs 32% (n=50) Anastrozole @ 24wk
event count · % of participants
Stable Disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
Progressive Disease 2.9% (n=102) vs 2% (n=50) Anastrozole @ 24wk
event count · % of participants
Progressive disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Tumor Size -32.35% (n=45) vs -42.88% (n=19) Anastrozole @ 20.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence

Breast Cancer

Shared mechanism: Estrogen receptor · full Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: April 2027 · NCT05774951 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Vepdegestrant · Veppanu

Marketed by Rigel Pharmaceuticals and partners

Approved in Breast Cancersmall molecule
Partial signal

NCT05654623 · Phase 3 · active, not recruiting

Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.

Next expected readout: December 2026 · NCT05909397 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)

Result source: NCT05654623

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Camizestrant: 4 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantVepdegestrant
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
7.8%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
—a
NCT05549505 · Phase 2 · registry result, not featured evidence
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
4%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
a
hot flush 24.8%
asthenia 20.8%
constipation 15.8%
NCT05549505 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Vepdegestrant

PFS 3.7 vs 3.6 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5 vs 2.1 Fulvestrant months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 10.9% (n=221) vs 3.6% (n=222) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 34.3% (n=274) vs 28.7% (n=272) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response NA vs 7.4 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Ki-67 Expression -71.4% (n=93) vs -72.9% (n=46) Anastrozole @ 2.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 71.4 Percent reduction as posted
Pathological Complete 1% (n=102) vs 0% (n=50) Anastrozole @ 22.57wk
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
mPEPI Score 0 20.6% (n=102) vs 20% (n=50) Anastrozole @ 22.57wk
event count · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
Breast Conserving Surgery 69.6% (n=102) vs 54% (n=50) Anastrozole
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
Stable Disease 37.3% (n=102) vs 32% (n=50) Anastrozole @ 24wk
event count · % of participants
Stable Disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
Progressive Disease 2.9% (n=102) vs 2% (n=50) Anastrozole @ 24wk
event count · % of participants
Progressive disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Tumor Size -32.35% (n=45) vs -42.88% (n=19) Anastrozole @ 20.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Vepdegestrant's landscape